(HRTX)

Reporting relationship: Chief Operating Officer
Issuer ticker: HRTX
Reported as of: 06 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Aug 2026, 10:18:44 UTC
Prior SEC filing: 03 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/Kathryn Lester Attorney-in-fact for Mark E. Hensley

Key filing fact

Mark E. Hensley filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 10 Aug 2026.

Key facts

This page summarizes Mark E. Hensley's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Aug 2026, 10:18.

Change

Previous filing in this sequence was filed on 03 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002065816 Primary reporting owner

Hensley Mark Earl

Relationship: Chief Operating Officer
Address: 25 FENTON MAIN STREET, SUITE 300, CARY
Signature: /s/Kathryn Lester Attorney-in-fact for Mark E. Hensley
Signature date: 10 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HRTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +31,250
Change %: +21%
Price
Shares after: 179,789
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1

HRTX transaction

Common Stock

Tax liability

Transaction value
Shares: -8,888
Change %: -4.9%
Price: $0.5000^*
Shares after: 170,901
Date: 06 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HRTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -31,250
Change %: -8.3%
Price: $0.000000^*
Shares after: 343,750
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,250
Exercise price: $0.000000
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F2

The restricted stock units vest with 25% upon the first anniversary of date of grant (May 6, 2025) and then in twelve (12) equal quarterly installments thereafter.